Related Experiment Videos
[Adjuvant chemotherapy]
A Del Nero1, A Mandressi, G Longo
1Istituto di Urologia, Università di Milano.
Archivio Italiano Di Urologia, Nefrologia, Andrologia : Organo Ufficiale Dell'Associazione Per La Ricerca in Urologia = Urological, Nephrological, and Andrological Sciences
|June 1, 1991
Abstract:
The authors treated 10 advanced renal cell carcinoma with circadian venous continuous infusion of 5-Fluoro 2-Deoxyuridine (FUDR). The drug was delivered by Medtronic Synchromed implantable pump in 14-day cycles alternating with 14-day intervals of physiologic saline infusion. Of the patient observed for at least 8 months (range: 8-32, median: 22.1) 1 showed progression. Circadian continuous central venous infusion of FUDR is minimally toxic. The FUDR can be delivered safely and conveniently in this way for long spans. This therapy is administrated in on entirely out patient setting, and associated with a normal quality of life.